Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s ...
Sabina Nieto is a Biology and Public Health student at UC Berkeley who is bridging the gap between molecular mechanisms and the broader public health dynamics that shape our healthcare system. We sat ...
TEDCO, the Maryland Technology Development Corporation, announced on October 5, 2026 that it has accepted a Federal and State Technology (FAST) Partnership Program grant from the U.S. Small Business ...
The National Center to Accelerate Cures (NCAC) today, October 1, 2026 announced its official launch as a national initiative dedicated to advancing ...
Jazz Pharmaceuticals plc, the Dublin-headquartered biopharma with a major U.S. hub in Philadelphia, announced on September 15, 2026 that it completed its acquisition of Actio Biosciences, Inc. for an ...
The University of Maryland School of Public Health announced on September 15, 2026 a $2.5 million grant from the National Institutes of Health to fund what’s described as the largest study to date on ...
Georgiamune, a Gaithersburg, Maryland-based clinical-stage biotech with roughly 30 employees, is reported to be raising approximately $93 million in Series B financing to advance its cancer and ...
Velocity Clinical Research has appointed Justin Starzyk as Chief Executive Officer, succeeding Paul Evans, who is transitioning to Chair of the Board. “Leading Velocity has been the privilege of my ...
SK pharmteco announced on September 22, 2026 an expanded manufacturing collaboration with Philadelphia-based Gemma Biotherapeutics (“GEMMABio”), supplying critical clinical trial materials for ...
Hovione, a globally-integrated pharmaceutical contract development and manufacturing organization (CDMO), announced on September 16, 2026 the opening of 89 Twin Rivers, a new 31,000-square-foot ...
OS Therapies Aligns With FDA on Phase 3 Design, Accepts MHRA’s Project Orbis Invitation for OST-HER2
OS Therapies, Inc., a Rockville, Maryland- and New York-based clinical-stage oncology company, announced on September 17, 2026 that it has achieved incremental alignment with the FDA on the adaptive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results